DrugEYE™, Data-driven drug discovery
DrugEYE™ provides Pharmaceutical companies, Research laboratories and Health authorities, precious foreknowledge about any emerging organism (virus, bacteria) immediately after it is detected and based on simple input. DrugEYE™ generates its output off-laboratory in a fully data driven way, saving months of wet lab research and funnelling the researcher’s efforts into the right direction.
- Functional characterization of the organism’s genes
- Prediction of the long term impacts on the human body
- Shortlist of candidate molecules to feed the drug discovery
Dynamic customer segmentation
Customer needs and expectations are changing rapidly, and traditional multi-criteria segmentation or clustering methods are no longer sufficient to act on the rapidly changing customer needs. The solutions allows to anticipate on customer needs based on a robust modelling of their behaviour and preferences, giving your company a leap ahead of the competition.
- AI inferred customer segmentation
- Automatic update of the segmentation identifying emerging customer behavioural patterns
- Ongoing recommendation engine for up-selling, cross-selling, Next Best Opportunities, Next Best Actions, best channel
Related news
We at MajestEYE are proud to announce a new partnership with FiSer Consulting. Our partnership will bring our respective solutions together to enhance the delivery of FiSer consulting services to…
Digital Transformation is an umbrella term for how businesses adapt their business models to accommodate new technologies like Artificial Intelligence (AI) and big data analytics, enabling them to understand their…
MajestEYE is selected by JICA , the Japanese International Cooperation Agency, among the top 10 most innovative start-ups in Africa in the framework of the international innovation competition NINJA (Next…
MajestEYE was selected by JICA, the Japanese International Cooperation Agency, among the top 10 most innovative start-ups in Africa for its Artificial Intelligence solution DrugEYE™, which sets to disrupt the…
